Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director Richard Buller sold 3,000 shares of Celcuity stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $105.69, for a total transaction of $317,070.00. Following the sale, the director owned 6,760 shares in the company, valued at $714,464.40. This represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Celcuity Price Performance
Shares of CELC stock opened at $102.72 on Wednesday. The firm has a fifty day simple moving average of $76.84 and a 200-day simple moving average of $47.73. The company has a market capitalization of $4.75 billion, a PE ratio of -27.99 and a beta of 0.21. Celcuity, Inc. has a twelve month low of $7.57 and a twelve month high of $108.91. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.
Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.13. Equities research analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently commented on CELC. HC Wainwright reissued a "neutral" rating and issued a $94.00 price target (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Guggenheim started coverage on Celcuity in a research note on Monday, September 22nd. They set a "buy" rating for the company. Craig Hallum raised their price target on shares of Celcuity from $96.00 to $108.00 and gave the stock a "buy" rating in a research report on Thursday, November 13th. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a report on Monday, October 20th. Finally, Wall Street Zen downgraded shares of Celcuity from a "hold" rating to a "sell" rating in a research note on Sunday, October 26th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $102.29.
View Our Latest Report on CELC
Institutional Investors Weigh In On Celcuity
Several institutional investors and hedge funds have recently made changes to their positions in CELC. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity in the third quarter worth $27,000. US Bancorp DE lifted its position in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after buying an additional 143 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after buying an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock valued at $74,000 after buying an additional 3,766 shares during the period. Finally, Avanza Fonder AB bought a new stake in shares of Celcuity during the 3rd quarter valued at about $79,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Celcuity Company Profile
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
